mlsanityData to 7 Oct 2026

DiscoVerse: Multi-Agent Pharmaceutical Co-Scientist for Traceable Drug Discovery and Reverse Translation

arXiv 2511.18259 ↗First posted 23 Nov 2025cs.CL cs.MAcited by 0

Not on the map. Why?

Abstract (arXiv)

Pharmaceutical research and development has accumulated vast and heterogeneous archives of data. Much of this knowledge stems from discontinued programs, and reusing these archives is invaluable for reverse translation. However, in practice, such reuse is often infeasible. In this work, we introduce DiscoVerse, a multi-agent co-scientist designed to support pharmaceutical research and development at Roche. Designed as a human-in-the-loop assistant, DiscoVerse enables domain-specific queries by delivering evidence-based answers: it retrieves relevant data, links across documents, summarises key findings and preserves institutional memory. We assess DiscoVerse through expert evaluation of source-linked outputs. Our evaluation spans a selected subset of 180 molecules from Roche's research and development repositories, encompassing over 0.87 billion BPE tokens and more than four decades of research. To our knowledge, this represents the first agentic framework to be systematically assessed on real pharmaceutical data for reverse translation, enabled by authorized access to confidential archives covering the full lifecycle of drug development. Our contributions include: role-specialized agent designs aligned with scientist workflows; human-in-the-loop support for reverse translation; expert evaluation; and a large-scale demonstration showing promising decision-making insights. In brief, across seven benchmark queries, DiscoVerse achieved near-perfect recall (≥ 0.99) with moderate precision (0.71-0.91). Qualitative assessments and three real-world pharmaceutical use cases further showed faithful, source-linked synthesis across preclinical and clinical evidence.

Key facts. No citing papers in the map yet (data through 7 Oct 2026). Builds on 31 of its 72 references that are in the map. First posted on arXiv 23 Nov 2025.

Builds on

31 of 72 references.

References · 31

  1. 2020Language Models are Few-Shot Learnerscited by 32,199
  2. 2023GPT-4 Technical Reportcited by 18,132
  3. 2022Chain-of-Thought Prompting Elicits Reasoning in Large Language Modelscited by 12,302
  4. 2025DeepSeek-R1: Incentivizing Reasoning Capability in LLMs via Reinforcement Learningcited by 6,146
  5. 2023Qwen Technical Reportcited by 3,273
  6. 2015Neural Machine Translation of Rare Words with Subword Unitscited by 2,898
  7. 2022Emergent Abilities of Large Language Modelscited by 2,483
  8. 2023MetaGPT: Meta Programming for A Multi-Agent Collaborative Frameworkcited by 1,761
  9. 2023Adapted Large Language Models Can Outperform Medical Experts in Clinical Text Summarizationcited by 244
  10. 2023Query Rewriting for Retrieval-Augmented Large Language Modelscited by 211
  11. 2024AI Agents That Mattercited by 199
  12. 2024Rethinking the Bounds of LLM Reasoning: Are Multi-Agent Discussions the Key?cited by 153
19 more
  1. 2023Emergent autonomous scientific research capabilities of large language modelscited by 127
  2. 2024BioDiscoveryAgent: An AI Agent for Designing Genetic Perturbation Experimentscited by 49
  3. 2023TELeR: A General Taxonomy of LLM Prompts for Benchmarking Complex Taskscited by 48
  4. 2025TxGemma: Efficient and Agentic LLMs for Therapeuticscited by 40
  5. 2024Zero-Shot Clinical Trial Patient Matching with LLMscited by 35
  6. 2025BioReason: Incentivizing Multimodal Biological Reasoning within a DNA-LLM Modelcited by 35
  7. 2025Generalization Bias in Large Language Model Summarization of Scientific Researchcited by 30
  8. 2025MedAgentBoard: Benchmarking Multi-Agent Collaboration with Conventional Methods for Diverse Medical Taskscited by 29
  9. 2024ColaCare: Enhancing Electronic Health Record Modeling through Large Language Model-Driven Multi-Agent Collaborationcited by 23
  10. 2024Position: Understanding LLMs Requires More Than Statistical Generalizationcited by 20
  11. 2025PharmAgents: Building a Virtual Pharma with Large Language Model Agentscited by 20
  12. 2023Automated Metrics for Medical Multi-Document Summarization Disagree with Human Evaluationscited by 18
  13. 2024A Comparative Study of Quality Evaluation Methods for Text Summarizationcited by 13
  14. 2025Artificial Intelligence Should Genuinely Support Clinical Reasoning and Decision Making To Bridge the Translational Gapcited by 13
  15. 2025HealthFlow: A Self-Evolving AI Agent with Meta Planning for Autonomous Healthcare Researchcited by 10
  16. 2025Rethinking Retrieval-Augmented Generation for Medicine: A Large-Scale, Systematic Expert Evaluation and Practical Insightscited by 6
  17. 2025SMMILE: An Expert-Driven Benchmark for Multimodal Medical In-Context Learningcited by 5
  18. 2024Exploring Language Model Generalization in Low-Resource Extractive QAcited by 2
  19. 2025AI Agents in Drug Discoverycited by 2

Built on by

Not cited yet.

Similar, not cited

Close in wording, no citation either way

  1. 2026BioResearcher: Scenario-Guided Multi-Agent for Translational Medicine
  2. 2026From Benchmark to Bench: Can Agents Survive Real-World Drug Discovery?
  3. 2025Conversational No-code, Multi-agentic Disease Module Identification and Drug Repurposing Prediction with ChatDRex
  4. 2024DrugAgent: Automating AI-aided Drug Discovery Programming through LLM Multi-Agent Collaboration
  5. 2025DrugMCTS: a drug repurposing framework combining multi-agent, RAG and Monte Carlo Tree Search
  6. 2025Exploring Modularity of Agentic Systems for Drug Discovery
  7. 2025RAG-Enhanced Collaborative LLM Agents for Drug Discovery
  8. 2025FROGENT: An End-to-End Full-process Drug Design Multi-Agent System